Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Goodwin Biotechnology Inks First Commercial Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Goodwin Biotechnology Inks First Commercial Contract

Company will showcase expertise in bringing a product from clinical trials through commercial supply.

By: Anthony Vecchione

Goodwin Biotechnology Inc. (GBI) signed their first master supply agreement for commercializing an antibody.

With the development of this new partnership, GBI’s integrated contract development and manufacturing organization (CDMO) biologics services will showcase their expertise in bringing a product from clinical trials through commercial supply while providing manufacturing of both drug substance and drug products.

“This is a major milestone in our journey and a validation of the efforts our team has put into evolving GBI, and this is only the next step of many more exciting accomplishments as we continue our evolution,” said CEO Darrin Schellin.

In a statement, the company said that it is looking forward to expanding its horizons and has set new milestones with its new partnership.

Karl Pinto, chairman of the board at GBI, said, “We have always invested and grown while supporting our clients’ success, and this agreement is a testament to the partnership we have built over many years with this key client.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics